The Promise of Precision Medicine, One Gene at a Time

A promising discovery about one of pregnancy's most dangerous complications is a reminder of how precision medicine actually advances — and of the obligation that comes with every step forward.

Preeclampsia is a leading cause of maternal and fetal death worldwide, and for all its severity, it has remained stubbornly hard to understand. It is typically defined by high blood pressure after twenty weeks of pregnancy, but the reality is rarely that tidy. The symptoms are inconsistent, the diagnosis is uncertain, and — remarkably, in the year 2026 — there is still no treatment beyond managing the pregnancy through delivery. Even delivery is not truly a cure: preeclampsia leaves a lifelong elevated risk of heart disease and stroke.

How blunt are today's tools? Consider the account, reported recently in National Geographic, of an obstetrician who specializes in this very condition and who lived through two preeclamptic pregnancies herself. Even as an expert, she says she still cannot say with confidence whether her son needed to be delivered at thirty-five weeks. Some of her markers were elevated; others were not. When a specialist who studies the disease cannot get a clear answer about her own case, we are looking at the limits of imprecise medicine — medicine that manages symptoms because it cannot yet see the cause.

A breakthrough from an unexpected place

That may be beginning to change. As National Geographic reported, a research team led by a dermatologist and immunologist at the University of Michigan — scientists who set out to study why autoimmune disease is more common in women — followed an unexpected thread from the skin to the placenta. Publishing in the American Heart Association journal Circulation, they identified a gene, VGLL3, that is highly expressed in both women's skin and the placenta, and proposed that its dysregulation may be a root cause of preeclampsia. If VGLL3 can be targeted and controlled, they suggest, it could open new possibilities for diagnosing, treating, and even preventing the condition.

It is early, and the researchers are careful to say so; preeclampsia likely has more than one root, and VGLL3 is one promising lead rather than a finished cure. But what makes the finding significant is not that it ends the story. It is that it begins one — the story precision medicine has told, over and over, across the last generation of medicine.

How precision medicine advances

Precision medicine does not arrive all at once. It advances one condition at a time, and almost always in the same way: we move from managing a disease by its outward signs to understanding — and then targeting — the specific biology that drives it.

We have watched this happen. Breast cancer was transformed when researchers identified molecular drivers such as HER2 and inherited risk genes like BRCA1 and BRCA2 — turning a single disease into distinct, biologically defined conditions that can be screened for, stratified by risk, and matched to targeted therapy. Cervical cancer was transformed when its cause was traced to HPV, which made both screening and a preventive vaccine possible. In each case, finding the biological root converted a disease that was once managed blindly into one that can be predicted, targeted, and in some cases prevented.

VGLL3 and preeclampsia may be the earliest chapter of that same arc — the moment a condition that has been managed by crude thresholds for a century begins to yield its underlying biology. If it follows the path that cancer genetics has traveled, it points toward a future in which a mother's risk can be understood before symptoms appear, monitored precisely, and one day treated at its source rather than ended by early delivery.

The promise, and the obligation

But a promise is only kept when it is delivered. And here is the uncomfortable truth that every advance like this one sharpens: the benefits of precision medicine too often reach only those who can be treated at major academic medical centers. A discovery made in a research laboratory does not, by itself, help a mother in a rural county who cannot reach a maternal-fetal specialist, or a patient whose community hospital has no path to the testing and expertise a breakthrough requires.

That gap is precisely why Intersect exists. Findings like the VGLL3 discovery deepen our commitment to ensuring that the benefits of precision medicine are not restricted to those with access to academic centers — but reach the community and rural settings where the need is greatest and the distance is longest. Maternal health is one of the areas our platform serves, and the principle holds across all of them: every advance in understanding raises the stakes on delivery.

The science will keep moving, one gene at a time. Our work is to make sure that when it does, the people who have always been furthest from the frontier are not the last to feel its benefits — but among the first.